Q J Med 1999; 92: 223-232
© 1999 Association of Physicians
Commentary |
Genetic markers to predict polygenic disease: a new problem for social genetics
From the Department of Human Metabolism and Genetics, St. Bartholomew's Hospital, London, and 1 Centre for Clinical Science & Measurement, School of Biological Sciences, University of Surrey, Guildford, Surrey, UK
Professor D.J. Galton, Department of Human Metabolism and Genetics, St Bartholomew's Hospital, London EC1A 7BE
Many genetic markers that relate to common multifactorial disease in adults have been identified during the past 15 years. Their use as adjuncts for the diagnosis, prognosis, prediction of disease or targeting therapy for these disorders has begun, good examples being the Factor V Leiden mutation for venous-thromboembolism, lipoprotein lipase mutations for hypertriglyceridaemia and the apolipoprotein E4 variant for Alzheimer's dementia. However, extensive genegene and geneenvironment interactions make their use more complex than markers for the simpler monogenic disorders (such as cystic fibrosis, or Duchennne's muscular dystrophy). Possible misapplication of the genetic markers for multifactorial disease in the fields of risk prediction, direct sales to the public, life assurance, employment rights, and legislation for regulation of their use are discussed.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. R. Golomb, B. P. Garg, L. E. Walsh, and L. S. Williams Perinatal stroke in baby, prothrombotic gene in mom: Does this affect maternal health insurance? Neurology, July 12, 2005; 65(1): 13 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cushman Inherited Risk Factors for Venous Thrombosis Hematology, January 1, 2005; 2005(1): 452 - 457. [Abstract] [Full Text] [PDF] |
||||

